Cost Effectiveness of Exenatide vs Insulin Glargine for Type 2 Diabetes
Author Information
Author(s): Woehl Anette, Evans Mark, Tetlow Anthony P, McEwan Philip
Primary Institution: Cardiff University
Hypothesis
Is exenatide a cost-effective treatment compared to insulin glargine for patients with sub-optimally controlled Type 2 diabetes in the UK?
Conclusion
Insulin glargine is more cost-effective than exenatide for managing Type 2 diabetes, as exenatide does not provide sufficient benefits to justify its higher cost.
Supporting Evidence
- Exenatide was associated with higher rates of daytime hypoglycaemia compared to insulin glargine.
- Patients treated with exenatide experienced significant weight loss, while those on insulin glargine gained weight.
- The cost-effectiveness ratio for exenatide was found to be -£29,149/QALY, indicating it is not cost-effective compared to insulin glargine.
Takeaway
This study looked at two diabetes treatments and found that one is cheaper and works better than the other, so it's a better choice for patients.
Methodology
A discrete event simulation model was used to forecast costs and health outcomes over a 40-year period for a cohort of 1,000 subjects with Type 2 diabetes.
Potential Biases
The study may be biased due to reliance on previously published data and assumptions made in the model.
Limitations
The model's predictions depend on the accuracy of the input data and may not fully capture all diabetes-related complications.
Participant Demographics
{"age":59,"gender":"56% male","BMI":31.9,"weight":89.8,"height":1.67,"ethnicity":"1% black"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website